DK3212641T3 - Thiazoler som modulatorer af roryt - Google Patents
Thiazoler som modulatorer af roryt Download PDFInfo
- Publication number
- DK3212641T3 DK3212641T3 DK15794421.6T DK15794421T DK3212641T3 DK 3212641 T3 DK3212641 T3 DK 3212641T3 DK 15794421 T DK15794421 T DK 15794421T DK 3212641 T3 DK3212641 T3 DK 3212641T3
- Authority
- DK
- Denmark
- Prior art keywords
- alkyl
- optionally substituted
- mmol
- methyl
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Forbindelse med formel I:
formel I hvor ® er phenyl, pyridyl, pyrimidyl, pyrazinyl, eller pyridazyl; R1 er H, Cl, OCF3, C(i-4)alkyl, -CN, F, OC(i-4)alkyl, OCHF2, Br, I, eller cyclopropyl; hvor C(i-4)alkyl eventuelt er substitueret med op til seks fluoratomer; R2 er H, F, Cl, -CN, OC(i-4)alkyl, OCHF2, OCF3, cyclopropyl, eller C(i-4)alkyl; hvor C(i-4)alkyl eventuelt er substitueret med op til fem fluoratomer, og cyclopropyl eventuelt er substitueret med OH, CH3, CF3, -CN, og op til fem fluoratomer; eller R1 og R2 kan taget sammen med deres bundne ring A danne et fusioneret ringsystem valgt fra gruppen bestående af naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, quinolinyl, 2,3-dihydro-lH-indenyl, chromanyl, isochromanyl, og naphthyridinyl; hvor naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, quinolinyl, 2,3-dihydro-lH-indenyl, chromanyl, isochromanyl, og naphthyridinyl eventuelt er substitueret op til tre gange med F, C(i-3)alkyl, eller OC(i-3)alkyl; hvor hver substituent er valgt uafhængigt; hvor OC(i-3)alkyl og Q1-3) alkyl eventuelt er substitueret med op til fem fluoratomer; forudsat at R2 ikke kan være H hvis R1 er H; R3 er oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, tetrazolyl, l,2,4-oxadiazol-5(4H)-on-3-yl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, pyrrolyl, eller furanyl; hvor oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, pyrrolyl, eller furanyl eventuelt er substitueret med R6, og yderligere eventuelt er substitueret med en substituent valgt fra gruppen bestående
af F, CH3, og CF3; R6 er
C(i-6)alkyl, C(O)NH2, -CN, C(3-6)Cycloalkyl, NH2, NH(C(i-6)alkyl), N(C(i-6)alkyl)2, NHCO(C(i-6)alkyl), N(C(i-6)alkyl)CO(C(i-6)alkyl), NHSO2(C(i-6)alkyl), N(C(i-6)alkyl)SO2(C(i-6)alkyl), O(C(i-6)alkyl), C(O)NH2, CONH(C(i-e)alkyl), CON(C(i-6)alkyl)2, SO2NH2, SO2NH(C(i-6)alkyl), SO2NH(COC(i-6)alkyl), eller SO2N(C(i-6)alkyl)2; hvor C(i-6)alkyl eller C(3-6)Cycloalkyl yderligere eventuelt er substitueret med op til seks fluoratomer, CO2H, OH, -CN, C(O)NH2, NH2, OCHs, OCHF2, OCFs, -(CX2)m-, eller N(CH3)2; hvor m er 2, 3, 4, eller 5; X er H, eller F; hvor hver forekomst af X i et enkelt molekyle er uafhængigt defineret; R4 er C(3-8)Cycloalkyl, C(3-8)alkyl, OC(i-8)alkyl, phenyl, pyridyl, CH2SO2C(i-3;alkyl, NAXA2, CH2O-C(3-8)alkyl, O-C(3-8)Cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, thiadiazolyl, oxadiazolyl, isoxadiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, pyrrolyl, eller furanyl, hvor C(3-8)alkyl og O-C(3-8)alkyl eventuelt er substitueret med 1 til 4 substituenter uafhængigt valgt fra F, Cl, OH, OCH3, OCHF2, OCF3, og -CN; og C(3-8)Cycloalkyl, O-C(3-8)Cycloalkyl, tetrahydrofuranyl, tetrahydropyranyl, phenyl, thiadiazolyl, oxadiazolyl, isoxadiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, pyrrolyl, og furanyl eventuelt er substitueret med 1 til 4 substituenter uafhængigt valgt fra gruppen bestående af F, Cl, CHs, CHF2, CFs, OH, OCHs, OCHF2, OCFs, og -CN; A1 er H, eller C(i-4)alkyl; hvor C(i-4)alkyl eventuelt er substitueret med op til seks fluoratomer, Cl, -CN, OCH3, OCHF2, eller OCF3; A2 er C(i-6)alkyl, C(o-2)alkyl-C(3-6)Cycloalkyl,
CH2-CeH4-C(O)NH2, -CeH4-F, eller CH2-CCH; hvor C(i-6)alkyl, og C(o-2)alkyl-
C(3-6)Cycloalkyl eventuelt er substitueret med op til seks fluoratomer, Cl, -CN, OCHs, OCHFz, eller OCF3; eller A1 og A2 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af: thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, morpholinyl, azetidinyl, og aziridinyl; hvor piperidinyl, pyrrolidinyl, piperazinyl, morpholinyl, azetidinyl, og aziridinyl eventuelt er substitueret med CF3, CHF2, CH2F, CH2CH2F, C(i-2)alkyl, C(3-6)cycloalkyl, -CN, OH, CH2OH, F, Cl, OCH3, OCHF2, OCF3, -(CX2)nO(CX2)n-, eller -(CX2)n- og op til tre yderligere substituenter valgt fra gruppen bestående af CH3, og F; hvor n uafhængigt er 0, 1, 2, 3, eller 4; X er H, eller F; hvor hver forekomst af X i et enkelt molekyle er uafhængigt defineret; R5 er SO2NA3A4, CONA3A4, NA3A4, eller C(i-6)alkyl; hvor C(i-6)alkyl eventuelt er substitueret med OH, Cl, -CN, OCH3, OCHF2, OCF3, NA3A4, eller cyclopropyl, og op til seks fluoratomer; A3 er H, eller C(i-4)alkyl; hvor C(i-4)alkyl eventuelt er substitueret med OH, Cl, -CN, OCH3, OCHF2, eller OCF3; og op til seks fluoratomer; A4 er C(i-6)alkyl, C(3-6)Cycloalkyl, eller C(3-6)heterocycloalkyl; hvor C(i-6)alkyl eventuelt er substitueret med cyclopropyl, morpholinyl, OH, OCH3, C(O)NH2, Cl, -CN, OCHF2, OCF3 og yderligere substitueret med op til tre fluoratomer; og hvor C(3-6)Cycloalkyl, og C(3-6)heterocycloalkyl eventuelt er substitueret med CF3, CH3,-CN, C(O)NH2, og op til tre fluoratomer; Eller A3 og A4 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af azetidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, og aziridinyl hvor azetidinyl, piperidinyl, morpholinyl, piperazinyl pyrrolidinyl, og aziridinyl eventuelt er substitueret med op til fire grupper valgt fra gruppen bestående af CF3, OH, CH3, CH2F, og CHF2; og yderligere eventuelt er substitueret med op til seks fluoratomer; R7 er H, F, OH, OCHs, CHs, CHF2, CH2F, eller CF3; R8 er H, eller F; og farmaceutisk acceptable salte deraf.
2. Forbindelsen ifølge krav 1, hvor:
er
eller Z er N, eller CH; R1 er H, Cl, OCF3, C(i-3)alkyl, -CN, F, OC(i-3)alkyl, OCHF2, Br, I, eller cyclopropyl; hvor C(i-3)alkyl eventuelt er substitueret med op til fem fluoratomer; R2 er H, F, Cl, -CN, OCH3, OCHF2, OCF3, cyclopropyl, eller C(i-4)alkyl; hvor C(i-4)alkyl eventuelt er substitueret med op til fem fluoratomer, og cyclopropyl eventuelt er substitueret med OH, CH3, CF3, -CN, og op til fem fluoratomer; eller R1 og R2 kan taget sammen med deres bundne ring A danne et fusioneret ringsystem valgt fra gruppen bestående af naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, og quinolinyl, hvor naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, og quinolinyl eventuelt er substitueret med F, CHF2, CH2F, CF3, eller CH3; forudsat at R2 ikke kan være H hvis R1 er H; R3 er oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, tetrazolyl, l,2,4-oxadiazol-5(4H)-on-3-yl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, eller pyrrolyl; hvor oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, eller pyrrolyl eventuelt er substitueret med R6;
R6 er
C(i-4)alkyl, C(O)NH2, eller -CN; hvor C(i-4)alkyl eventuelt er substitueret med op til seks fluoratomer, CO2H, OH, eller -CN; R4 er C(3-6)Cycloalkyl, isopropyl, C(CH3)2OCH3, OC(i-4)alkyl, fluorphenyl, difluorphenyl, pyridyl, CH2SO2CH3, eller NAW, hvor C(3-6)Cycloalkyl eventuelt er substitueret med OCH3, to fluorgrupper eller to methylgrupper; A1 er H, eller C(i-3)alkyl; hvor C(i-3)alkyl eventuelt er substitueret med op til fem fluoratomer, Cl, -CN, OCH3, OCHF2, eller OCF3; A2 er C(i-4)alkyl, C(o-2)alkyl-C(3-6)Cycloalkyl, CH2-CeH4-C(O)NH2, -CeH4-F, eller CH2-CCH; hvor C(i-4)alkyl, og C(o-2)alkyl-C(3-6)Cycloalkyl eventuelt er substitueret med op til tre fluoratomer, Cl, -CN, OCH3, OCHF2, eller OCF3; eller A1 og A2 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af:
thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, og morpholinyl; hvor piperidinyl, pyrrolidinyl, piperazinyl, og morpholinyl eventuelt er substitueret med CF3, CH2F, CH2CH2F, C(i-2)alkyl, -CN, OH, CH2OH, F, Cl, OCH3, OCHF2, eller OCF3, og op til tre yderligere substituenter valgt fra gruppen bestående af CH3, og F; R5 er SO2NA3A4, C(i-6)alkyl,
hvor C(i-6)alkyl eventuelt er substitueret med OH, Cl, -CN, OCH3, OCHF2, OCF3, eller NA3A4; og op til seks fluoratomer; A4 er C(i-6)alkyl, C(3-6)Cycloalkyl, oxetanyl, eller tetrahydrofuranyl; hvor C(i-6)alkyl eventuelt er substitueret med cyclopropyl, morpholinyl, OH, OCH3, eller C(O)NH2, og yderligere substitueret med op til tre fluoratomer; og hvor C(3-6)Cycloalkyl, oxetanyl, og tetrahydrofuranyl eventuelt er substitueret med CF3, CH3, -CN, eller C(O)NH2; eller A3 og A4 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af azetidinyl, piperidinyl, morpholinyl, piperazinyl, og pyrrolidinyl hvor azetidinyl, piperidinyl, morpholinyl, og piperazinyl eventuelt er substitueret med op til fire groupper valgt fra gruppen bestående af CF3, OH, og CH3; og yderligere eventuelt er substitueret med op til seks fluoratomer; R7 er H, F, OH, eller OCHs; R8 er H; og farmaceutisk acceptable salte deraf.
3. Forbindelsen ifølge krav 2, hvor: er
R1 er H, Cl, OCF3, C(i-3)alkyl, -CN, F, 0C(i-3)alkyl, OCHF2, eller cyclopropyl, hvor C(i-2)alkyl eventuelt er substitueret med op til fem fluoratomer; R2 er CHF2, CFs, H, F, Cl, -CN,
eller R1 og R2 kan taget sammen med deres bundne ring A danne et fusioneret ringsystem valgt fra gruppen bestående af naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, og quinolinyl, hvor naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, og quinolinyl eventuelt er substitueret med F, CHF2, CH2F, CF3, eller CH3; forudsat at R2 ikke kan være H hvis R1 er H; R3 er oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, tetrazolyl, l,2,4-oxadiazol-5(4H)-on-3-yl, pyridyl, pyrimidyl, pyridazyl, eller pyrazyl; hvor oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, pyridyl, pyrimidyl, pyridazyl, eller pyrazyl eventuelt er substitueret med R6; R6 er
C(i-2)alkyl, CH2C(CH3)2CO2H, C(o-i)alkylC(CH3)20H, CH2C(CH3)2CN, C(O)NH2, eller -CN; hvor C(i-2)alkyl eventuelt er substitueret med op til fem fluoratomer; R4 er C(3-6)Cycloalkyl, isopropyl, C(CH3)2OCH3, OC(i-4)alkyl, fluorphenyl, difluorphenyl, pyridyl, CH2SO2CH3, eller NA4A2, hvor C(3-6)Cycloalkyl
eventuelt er substitueret med OCH3, to fluorgrupper eller to methylgrupper; A1 er H, eller C(i-3)alkyl; hvor C(i-3)alkyl eventuelt er substitueret med op til fem fluoratomer; A2 er C(i-4)alkyl, C(o-2)alkyl-C(3-6)Cycloalkyl, CH2-CeH4-C(O)NH2, -CehU-F, CH2-CCH, eller CH2CH2-CN; hvor C(i-4)alkyl, og C(o-2)alkyl-C(3-6)Cycloalkyl eventuelt er substitueret med op til tre fluoratomer; eller A1 og A2 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af:
thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, og morpholinyl; hvor piperidinyl, pyrrolidinyl, piperazinyl, og morpholinyl eventuelt er substitueret med CF3, CH2F, CH2CH2F, C(i-2)alkyl, -CN, OH, CH2OH, eller F, og op til tre yderligere substituenter valgt fra gruppen bestående af CH3, og F; R5 er SO2NA3A4, C(i-6)alkyl,
eller
hvor C(i-6)alkyl eventuelt er substitueret med OH, OCH3, eller, NA3A4, og op til seks fluoratomer; A3 er H, eller C(i-4)alkyl; A4 er C(i-6)alkyl, cyclopropyl, cyclobutyl, oxetanyl, eller tetrahydrofuranyl; hvor C(i-6)alkyl eventuelt er substitueret med cyclopropyl, morpholinyl, OH, OCH3, eller C(O)NH2, og yderligere substitueret med op til tre fluoratomer;
og hvor cyclopropyl cyclobutyl, oxetanyl, og tetrahydrofuranyl eventuelt er substitueret med CF3, CH3, -CN, eller C(O)NH2; eller A3 og A4 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af aztetidinyl, piperidinyl, morpholinyl, piperazinyl, og pyrrolidinyl hvor azetidinyl, piperidinyl, morpholinyl, og piperazinyl eventuelt er substitueret med op til to grupper valgt fra gruppen bestående af CF3, OH, og CH3; og yderligere eventuelt er substitueret med op til tre fluoratomer; og farmaceutisk acceptable salte deraf.
4. Forbindelsen ifølge krav 3, hvor:
er
R1 er H, Cl, OCFs, CFs, CHF2, C(i-3)alkyl, -CN, F, OC(i-3)alkyl, eller OCHF2; R2 er CHF2, CFs, H, F, Cl,
eller R1 og R2 kan taget sammen med deres bundne ring A danne et fusioneret ringsystem valgt fra gruppen bestående af naphthalenyl, isoquinolinyl, og tetrahydronaphthalenyl; forudsat at R2 ikke kan være H hvis R1 er H; R3 er oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, tetrazolyl, l,2,4-oxadiazol-5(4H)-on-3-yl, pyridyl, eller
pyrimidyl, hvor oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, pyridyl eller pyrimidyl eventuelt er substitueret med R6; R6 er
CHs, CH2C(CH3)2CO2H, C(o-i)alkylC(CH3)2OH, CH2C(CH3)2CN, eller C(O)NH2; R4 er C(3-6)Cycloalkyl, isopropyl, C(CH3)2OCH3, OCH(CH3)2, OC(CH3)3, fluorphenyl, difluorphenyl, eller NAW, hvor C(3-6)Cycloalkyl eventuelt er substitueret med OCH3, to fluorgrupper eller to methylgrupper; A1 er H, C(i-3)alkyl, eller CH2CH2F; A2 er C(2-4)alkyl, CH2-cyclopentyl, CH2CH2-cyclopropyl, C(3-4)Cycloalkyl,
CH2-C6H4-C(O)NH2, -CeFU-F, CH2-CCH, eller CH2CH2-CN; hvor C(3-4)cycloalkyl eventuelt er substitueret med et fluoratom og C(2-4)alkyl eventuelt er substitueret med op til tre fluoratomer; eller A1 og A2 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af:
thiomorpholinyl, piperidinyl, pyrrolidinyl, og morpholinyl; hvor piperidinyl, og pyrrolidinyl eventuelt er substitueret med CF3, CH2F, CH2CH2F, C(i-2)alkyl, -CN, OH, eller CH2OH, og op til tre yderligere substituenter valgt fra gruppen bestående af CH3, og F; R5 er SO2NA3A4, C(CF3)2OH,
A3 er H, CHsCHz, eller C(CH3)3; A4 er C(i-6)alkyl,
C(CH3)2CH2OCH3, C(CH3)2CH2OH, C(CH3)2CH2-morpholinyl, C(CH3)2CH2CH2OH, C(CH3)2CH2C(O)NH2, eller CH2C(CHs)2OH; hvor C(i-6)alkyl eventuelt er substitueret med op til tre fluoratomer; eller A3 og A4 kan taget sammen med deres bundne nitrogen danne en ring valgt fra gruppen bestående af
og farmaceutisk acceptable salte deraf.
5. Forbindelsen ifølge krav 4, hvor: R1 er H, Cl, OCFs, CFs, CHF2, eller F; R2 er CHF2, CFs, H, F, Cl,
eller
eller R1 og R2 kan taget sammen med deres bundne ring A danne et fusioneret ringsystem valgt fra gruppen bestående af naphthalenyl, og isoquinolinyl; forudsat at R2 ikke kan være H hvis R1 er H; R3 er
eller phenyl, hvor phenyl eventuelt er substitueret med R6; R6 er
CHs, CH2C(CH3)2CO2H, eller C(CH3)2OH; R4 er C(4-6)Cycloalkyl, isopropyl, C(CH3)2OCH3, OCH(CH3)2, difluorpiperidinyl, fluorpiperidinyl, fluorphenyl, eller NAW, hvor C(4-6)Cycloalkyl eventuelt er substitueret med OCH3, to fluorgrupper eller to methylgrupper; og hvor A1 og A2 taget sammen med deres bundne nitrogen danner en pyrrolidinylring, hvor pyrrolidinylringen eventuelt er substitueret med CH3, CH2F, og op til tre yderligere substituenter valgt fra gruppen bestående af CH3, og F; R5 er SO2NA3A4, C(CF3)2OH,
A3 er H; A4 er
og farmaceutisk acceptable salte deraf.
6. Forbindelsen ifølge krav 5 valgt fra gruppen bestående af:
og farmaceutisk acceptable salte deraf.
7. Forbindelsen ifølge krav 4 valgt fra gruppen bestående af:
og farmaceutisk acceptable salte deraf.
8. Farmaceutisk sammensætning, omfattende en forbindelse ifølge krav 1 og en farmaceutisk acceptabel bærer.
9. Farmaceutisk sammensætning fremstillet ved at blande en forbindelse ifølge krav 1 og en farmaceutisk acceptabel bærer.
10. Fremgangsmåde til fremstilling af en farmaceutisk sammensætning omfattende at blande en forbindelse ifølge krav 1 og en farmaceutisk acceptabel bærer.
11. Forbindelse ifølge krav 1 til anvendelse i en fremgangsmåde til behandling eller lindring af et RORyt forårsaget inflammatorisk syndrom, lidelse eller sygdom omfattende at indgive til et individ med behov derfor en effektiv mængde af forbindelsen ifølge krav 1.
12. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er valgt fra gruppen bestående af: rheumatoid arthritis, psoriasis, kronisk obstruktiv lungesygdom, psoriasis artritis, ankyloserende spondylitis, Crohn's sygdom, neutrofil astma, steroid resistent astma, multipel sklerose, systemisk lupus erythematosus, og colitis ulcerosa.
13. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er psoriasis.
14. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er rheumatoid arthritis.
15. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er colitis ulcerosa.
16. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er Crohn's sygdom.
17. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er multipel sklerose.
18. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er neutrofil astma.
19. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er steroid resistent astma.
20. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er psoriasis artritis.
21. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er ankyloserende spondylitis.
22. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er systemisk lupus erythematosus.
23. Forbindelse til anvendelse ifølge krav 11, hvor sygdommen er kronisk obstruktiv lungesygdom.
24. Forbindelse ifølge krav 1 til anvendelse i en fremgangsmåde til behandling eller lindring af et syndrom, lidelse eller sygdom, hos et individ med behov derfor omfattende at indgive til individet en effektiv mængde af en forbindelse ifølge krav 1 eller sammensætning eller medikament deraf i en kombinationsterapi med ét eller flere anti-inflammatoriske midler, eller immunosuppressive midler, hvor syndromet, lidelsen eller sygdommen er valgt fra gruppen bestående af: rheumatoid arthritis, og psoriasis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072614P | 2014-10-30 | 2014-10-30 | |
PCT/US2015/058198 WO2016069976A1 (en) | 2014-10-30 | 2015-10-30 | THIAZOLES AS MODULATORS OF RORyt |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3212641T3 true DK3212641T3 (da) | 2019-03-04 |
Family
ID=54541228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15794421.6T DK3212641T3 (da) | 2014-10-30 | 2015-10-30 | Thiazoler som modulatorer af roryt |
Country Status (22)
Country | Link |
---|---|
US (2) | US9861618B2 (da) |
EP (1) | EP3212641B1 (da) |
JP (1) | JP6661630B2 (da) |
KR (1) | KR20170078748A (da) |
CN (1) | CN107108598B (da) |
AU (1) | AU2015339089B2 (da) |
BR (1) | BR112017008842A2 (da) |
CA (1) | CA2965515A1 (da) |
CY (1) | CY1121285T1 (da) |
DK (1) | DK3212641T3 (da) |
ES (1) | ES2708025T3 (da) |
HR (1) | HRP20190174T1 (da) |
IL (1) | IL251851A0 (da) |
LT (1) | LT3212641T (da) |
MA (1) | MA40863B1 (da) |
ME (1) | ME03306B (da) |
PL (1) | PL3212641T3 (da) |
PT (1) | PT3212641T (da) |
RS (1) | RS58250B1 (da) |
SI (1) | SI3212641T1 (da) |
TR (1) | TR201820513T4 (da) |
WO (1) | WO2016069976A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3212641B1 (en) | 2014-10-30 | 2018-12-05 | Janssen Pharmaceutica NV | Thiazoles as modulators of roryt |
JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
US11230555B2 (en) | 2018-03-12 | 2022-01-25 | Escalier Biosciences B.V. | Bicyclic RORγ modulators |
CA3093695A1 (en) | 2018-03-12 | 2019-09-19 | Escalier Biosciences B.V. | Spirocyclic ror-gamma modulators |
ES2929140T3 (es) | 2018-06-18 | 2022-11-25 | Janssen Pharmaceutica Nv | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat |
JP2021529161A (ja) | 2018-06-18 | 2021-10-28 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレーターとしてのピリジニルピラゾール |
CN112566901A (zh) | 2018-06-18 | 2021-03-26 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基取代的吡唑类 |
JP2021528398A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγTのモジュレーターとしての6−アミノピリジン−3−イルピラゾール |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
AU3201095A (en) | 1994-07-27 | 1996-02-22 | G.D. Searle & Co. | Substituted thiazoles for the treatment of inflammation |
BR0208956A (pt) | 2001-04-16 | 2004-07-13 | Tanabe Seiyaku Co | Abridor de canais de k ativados por cálcio de grande condutância |
NZ530772A (en) * | 2001-08-13 | 2006-03-31 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
US8188128B2 (en) | 2005-05-12 | 2012-05-29 | The University Of Medicine And Dentistry Of New Jersey | Opioid receptor subtype-selective agents |
TWI444370B (zh) | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
WO2008064318A2 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Peripheral opioid receptor active compounds |
WO2008064317A1 (en) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Lipophilic opioid receptor active compounds |
WO2009011850A2 (en) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
JP5681105B2 (ja) * | 2008-07-17 | 2015-03-04 | バイエル・クロップサイエンス・アーゲーBayer Cropscience Ag | 殺害虫剤として使用されるヘテロ環式化合物 |
AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
PT3002008T (pt) | 2010-03-11 | 2018-12-24 | Univ New York | Compostos de amido como moduladores roryt e suas utilizações |
US9101600B2 (en) | 2010-03-11 | 2015-08-11 | New York University | Compounds as RORγt modulators and uses thereof |
WO2011115892A1 (en) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
US9505798B2 (en) | 2010-11-29 | 2016-11-29 | New York University | Steroid compounds as RORyt modulators and uses thereof |
JP5981350B2 (ja) | 2010-12-28 | 2016-08-31 | ライオン株式会社 | 口腔状態の判定方法、並びにそのために用いられる分析用具、装置、及びプログラム |
WO2012129491A1 (en) * | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
WO2013018695A1 (ja) | 2011-07-29 | 2013-02-07 | 武田薬品工業株式会社 | 複素環化合物 |
BR112014005268A2 (pt) | 2011-09-09 | 2017-03-28 | Univ New York | compostos de amido como moduladores de ror t e usos dos mesmos |
WO2013079223A1 (en) | 2011-12-02 | 2013-06-06 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
MX2014014614A (es) | 2012-05-31 | 2015-02-12 | Phenex Pharmaceuticals Ag | Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano ror [gamma). |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
CN105308037B (zh) | 2013-06-04 | 2017-09-19 | 阿克图拉姆生命科学股份公司 | 三唑化合物及其作为γ分泌酶调节剂的用途 |
EP3044219A1 (en) | 2013-09-09 | 2016-07-20 | Bristol-Myers Squibb Company | Rorgamma modulators |
US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
CN105555768B (zh) | 2013-09-20 | 2018-10-16 | 百时美施贵宝公司 | RORγ调节剂 |
PL3077372T3 (pl) | 2013-12-05 | 2019-09-30 | Lead Pharma Holding B.V. | MODULATORY ROR GAMMA (RORγ) |
JP6548664B2 (ja) | 2014-01-06 | 2019-07-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | シクロヘキシルスルホンRORγ調節因子 |
ES2705400T3 (es) | 2014-01-06 | 2019-03-25 | Bristol Myers Squibb Co | Sulfonas heterocíclicas como moduladores de ROR gamma |
CA2936116A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators |
US9771320B2 (en) | 2014-01-06 | 2017-09-26 | Bristol-Myers Squibb Company | Carbocyclic sulfone RORγ modulators |
CA2942871A1 (en) | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
JP6695335B2 (ja) | 2014-10-30 | 2020-05-20 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレーターとしてのアミド置換チアゾール |
EP3212641B1 (en) | 2014-10-30 | 2018-12-05 | Janssen Pharmaceutica NV | Thiazoles as modulators of roryt |
-
2015
- 2015-10-30 EP EP15794421.6A patent/EP3212641B1/en active Active
- 2015-10-30 AU AU2015339089A patent/AU2015339089B2/en not_active Ceased
- 2015-10-30 BR BR112017008842A patent/BR112017008842A2/pt not_active Application Discontinuation
- 2015-10-30 JP JP2017523355A patent/JP6661630B2/ja not_active Expired - Fee Related
- 2015-10-30 RS RS20190112A patent/RS58250B1/sr unknown
- 2015-10-30 KR KR1020177014502A patent/KR20170078748A/ko not_active Application Discontinuation
- 2015-10-30 ES ES15794421T patent/ES2708025T3/es active Active
- 2015-10-30 CA CA2965515A patent/CA2965515A1/en not_active Abandoned
- 2015-10-30 DK DK15794421.6T patent/DK3212641T3/da active
- 2015-10-30 US US14/927,501 patent/US9861618B2/en active Active
- 2015-10-30 ME MEP-2019-25A patent/ME03306B/me unknown
- 2015-10-30 TR TR2018/20513T patent/TR201820513T4/tr unknown
- 2015-10-30 CN CN201580071984.5A patent/CN107108598B/zh not_active Expired - Fee Related
- 2015-10-30 LT LTEP15794421.6T patent/LT3212641T/lt unknown
- 2015-10-30 PT PT15794421T patent/PT3212641T/pt unknown
- 2015-10-30 SI SI201530538T patent/SI3212641T1/sl unknown
- 2015-10-30 PL PL15794421T patent/PL3212641T3/pl unknown
- 2015-10-30 MA MA40863A patent/MA40863B1/fr unknown
- 2015-10-30 WO PCT/US2015/058198 patent/WO2016069976A1/en active Application Filing
-
2017
- 2017-04-23 IL IL251851A patent/IL251851A0/en unknown
- 2017-11-14 US US15/812,528 patent/US10080744B2/en active Active
-
2019
- 2019-01-25 HR HRP20190174TT patent/HRP20190174T1/hr unknown
- 2019-02-27 CY CY20191100242T patent/CY1121285T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PL3212641T3 (pl) | 2019-05-31 |
LT3212641T (lt) | 2019-02-11 |
KR20170078748A (ko) | 2017-07-07 |
JP6661630B2 (ja) | 2020-03-11 |
PT3212641T (pt) | 2019-02-11 |
CN107108598A (zh) | 2017-08-29 |
WO2016069976A1 (en) | 2016-05-06 |
US20160120850A1 (en) | 2016-05-05 |
CY1121285T1 (el) | 2020-05-29 |
ES2708025T3 (es) | 2019-04-08 |
CN107108598B (zh) | 2020-11-17 |
IL251851A0 (en) | 2017-06-29 |
CA2965515A1 (en) | 2016-05-06 |
US20180064690A1 (en) | 2018-03-08 |
MA40863A (fr) | 2017-09-06 |
EP3212641A1 (en) | 2017-09-06 |
JP2017534626A (ja) | 2017-11-24 |
RS58250B1 (sr) | 2019-03-29 |
TR201820513T4 (tr) | 2019-02-21 |
BR112017008842A2 (pt) | 2017-12-26 |
AU2015339089B2 (en) | 2020-07-16 |
US9861618B2 (en) | 2018-01-09 |
SI3212641T1 (sl) | 2019-02-28 |
AU2015339089A1 (en) | 2017-05-11 |
EP3212641B1 (en) | 2018-12-05 |
MA40863B1 (fr) | 2018-12-31 |
US10080744B2 (en) | 2018-09-25 |
HRP20190174T1 (hr) | 2019-03-22 |
ME03306B (me) | 2019-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3212641T3 (da) | Thiazoler som modulatorer af roryt | |
JP6695335B2 (ja) | RORγtのモジュレーターとしてのアミド置換チアゾール | |
JP6623270B2 (ja) | Rorγtのモジュレーターとしてのトリフルオロメチルアルコール | |
US10975068B2 (en) | 6-aminopyridin-3-yl thiazoles as modulators of RORγT | |
EP3790865A1 (en) | Phenyl substituted pyrazoles as modulators of roryt | |
US20190382354A1 (en) | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT | |
JPWO2019022235A1 (ja) | 円形脱毛症の治療剤又は予防剤 |